Yuliya Lytvyn

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8045668/publications.pdf

Version: 2024-02-01

77 papers	1,979 citations	331538 21 h-index	265120 42 g-index
78 all docs	78 docs citations	78 times ranked	2802 citing authors

#	Article	IF	Citations
1	Biologic therapies associated with development of palmoplantar pustulosis and palmoplantar pustular psoriasis: a systematic review. International Journal of Dermatology, 2023, 62, 12-21.	0.5	3
2	Stewartâ€Treves syndrome and other cutaneous malignancies in the context of chronic lymphedema: a systematic review. International Journal of Dermatology, 2022, 61, 62-70.	0.5	7
3	Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review. Journal of Cutaneous Medicine and Surgery, 2022, 26, 79-86.	0.6	19
4	Cardiometabolic and Kidney Protection in Kidney Transplant Recipients With Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials. Transplantation, 2022, 106, 734-748.	0.5	6
5	Biologic treatment outcomes in mucous membrane pemphigoid: A systematic review. Journal of the American Academy of Dermatology, 2022, 87, 110-120.	0.6	15
6	Incidence and prognosis of COVIDâ€19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	7
7	Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study. JAAD International, 2022, 6, 3-5.	1.1	2
8	The association between physical activity time and neuropathy in longstanding type 1 diabetes: A cross-sectional analysis of the Canadian study of longevity in type 1 diabetes. Journal of Diabetes and Its Complications, 2022, 36, 108134.	1.2	5
9	Comparing the frequency of isotretinoin-induced hair loss at <0.5-mg/kg/d versus â‰¥0.5-mg/kg/d dosing in acne patients: A systematic review. JAAD International, 2022, 6, 125-142.	1.1	8
10	A Systematic Review Characterizing Psoriatic Arthritis Onset and Exacerbation in Patients Receiving Biologic Therapy. Journal of Cutaneous Medicine and Surgery, 2022, , 120347542210885.	0.6	1
11	Onset of Pyoderma Gangrenosum in Patients on Biologic Therapies: A Systematic Review. Advances in Skin and Wound Care, 2022, 35, 454-460.	0.5	2
12	Onset of Sarcoidosis in Patients on Biologic Therapy: A Systematic Review. Journal of Cutaneous Medicine and Surgery, 2022, 26, 512-513.	0.6	1
13	Lichenoid Drug Eruptions Associated With the Use of Biologic Therapy: A Systematic Review. Journal of Cutaneous Medicine and Surgery, 2022, 26, 521-522.	0.6	1
14	Development of granuloma annulare in patients on biologic therapies: A systematic review. Journal of the American Academy of Dermatology, 2021, 85, 1594-1597.	0.6	0
15	Development of morphea in patients receiving biologic therapies: A systematic review. Journal of the American Academy of Dermatology, 2021, 84, 1081-1085.	0.6	3
16	Drugs associated with development of pityriasis rubra pilaris: A systematic review. Journal of the American Academy of Dermatology, 2021, 84, 1071-1081.	0.6	7
17	Treatment outcomes in confluent and reticulated papillomatosis: A systematic review. Journal of the American Academy of Dermatology, 2021, 84, 825-829.	0.6	5
18	Changes in Cardiovascular Biomarkers Associated With the Sodiumâ€“Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes. Diabetes Care, 2021, 44, e45-e47.	4.3	22

#	Article	IF	Citations
19	Vasopressin associated with renal vascular resistance in adults with longstanding type 1 diabetes with and without diabetic kidney disease. Journal of Diabetes and Its Complications, 2021, 35, 107807.	1.2	8
20	Biologic treatment outcomes in refractory eosinophilic fasciitis: A systematic review of published reports. Journal of the American Academy of Dermatology, 2021, , .	0.6	2
21	A response to â€œCannabinoids in Dermatologic Surgeryâ€: The added considerations of factors affecting tissue perfusion, wound healing, and modes of administration in safety and efficacy of cannabinoids. Journal of the American Academy of Dermatology, 2021, 85, e385-e386.	0.6	1
22	Relationships between inflammation, hemodynamic function and RAAS in longstanding type 1 diabetes and diabetic kidney disease. Journal of Diabetes and Its Complications, 2021, 35, 107880.	1.2	8
23	Clinical manifestations and treatment outcomes in degos disease: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1655-1669.	1.3	2
24	Treatment outcomes in patients with papuloerythroderma of Ofuji: A systematic review. JAAD International, 2021, 3, 18-22.	1.1	6
25	Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 2466-2475.	2.2	17
26	Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes. Kidney International Reports, 2021, 6, 2095-2104.	0.4	23
27	Drug survival of guselkumab in patients with plaque psoriasis: A 2Âyear retrospective, multicenter study. JAAD International, 2021, 4, 49-51.	1.1	10
28	Renal Hemodynamics and Renin-Angiotensin-Aldosterone System Profiles in Patients With Heart Failure. Journal of Cardiac Failure, 2021, , .	0.7	3
29	Can We Separate Oral Lichen Planus from Allergic Contact Dermatitis and Should We Patch Test? A Systematic Review of Chronic Oral Lichenoid Lesions. Dermatitis, 2021, 32, 144-150.	0.8	6
30	A systematic review of eczematous eruptions in patients receiving biologic therapy. Journal of the American Academy of Dermatology, 2021, 85, 1630-1635.	0.6	5
31	The New Biology of Diabetic Kidney Diseaseâ€”Mechanisms and Therapeutic Implications. Endocrine Reviews, 2020, 41, 202-231.	8.9	77
32	SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes. Diabetes and Metabolism, 2020, 46, 203-209.	1.4	13
33	Stevens Johnson Syndrome and Toxic Epidermal Necrolysis Reactions to BRAF and MEK Inhibitors in Patients with Melanoma: A Systematic Review. Journal of the American Academy of Dermatology, 2020, 85, 981-983.	0.6	2
34	Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors inÂhyperfiltering people with type 1 diabetes andÂpeople with type 2 diabetes and normal kidney function. Kidney International, 2020, 97, 631-635.	2.6	29
35	Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment. Journal of the American Academy of Dermatology, 2020, 83, 579-586.	0.6	30
36	Mineralocorticoid Antagonism and Diabetic Kidney Disease. Current Diabetes Reports, 2019, 19, 4.	1.7	30

#	Article	IF	Citations
37	Elevated plasma cyclic guanosine monophosphate may explain greater efferent arteriolar tone in adults with longstanding type 1 diabetes: A brief report. Journal of Diabetes and Its Complications, 2019, 33, 547-549.	1.2	1
38	Estimating GFR by Serum Creatinine, Cystatin C, and Î²2-Microglobulin in Older Adults: Results From the Canadian Study of Longevity in Type 1 Diabetes. Kidney International Reports, 2019, 4, 786-796.	0.4	12
39	Risk factors for diabetic kidney disease in adults with longstanding type 1 diabetes: results from the Canadian Study of Longevity in Diabetes. Renal Failure, 2019, 41, 427-433.	0.8	4
40	Sodium glucose cotransporter (SGLT)â€2 inhibitors: Do we need them for glucoseâ€lowering, for cardiorenal protection or both?. Diabetes, Obesity and Metabolism, 2019, 21, 24-33.	2.2	17
41	Molecular regulation of the reninâ€“angiotensin system by sodiumâ€“glucose cotransporter 2 inhibition in type 1 diabetes mellitus. Diabetologia, 2019, 62, 1090-1093.	2.9	21
42	Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes. American Journal of Kidney Diseases, 2019, 73, 786-796.	2.1	15
43	Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1388-1398.	2.2	12
44	Role of Mitochondrial Aldehyde Dehydrogenase in Nitroglycerin-Mediated Vasodilation. Journal of Cardiovascular Pharmacology, 2019, 73, 359-364.	0.8	2
45	Bone mineral density in patients with longstanding type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2019, 33, 107324.	1.2	21
46	The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 575-583.	2.2	15
47	Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2019, 42, 273-280.	4.3	16
48	Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2018, 41, 831-839.	4.3	13
49	Response by Lytvyn et al to Letter Regarding Article, â€œSodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trialsâ€. Circulation, 2018, 137, 1984-1985.	1.6	1
50	Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. American Journal of Physiology - Renal Physiology, 2018, 314, F412-F422.	1.3	68
51	Diabetes Care Disparities in Long-standing Type 1 Diabetes in Canada and the U.S.: A Cross-sectional Comparison. Diabetes Care, 2018, 41, 88-95.	4.3	17
52	Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2018, 41, 2570-2578.	4.3	37
53	Cardiovascular Risk Reduction in PatientsÂWith Chronic Kidney Disease. Journal of the American College of Cardiology, 2018, 71, 2415-2418.	1.2	11
54	Sex differences in neuropathic pain in longstanding diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2018, 32, 660-664.	1.2	22

#	Article	IF	Citations
55	Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes. JCI Insight, 2018, 3, .	2.3	38
56	Influence of sex on hyperfiltration in patients with uncomplicated type 1 diabetes. American Journal of Physiology - Renal Physiology, 2017, 312, F599-F606.	1.3	22
57	Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes. Diabetes, 2017, 66, 1939-1949.	0.3	28
58	The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1 diabetes. American Journal of Physiology - Renal Physiology, 2017, 312, F335-F342.	1.3	33
59	Neuropathy and presence of emotional distress and depression in longstanding diabetes: Results from the Canadian study of longevity in type 1 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1318-1324.	1.2	37
60	Urinary adenosine excretion in type 1 diabetes. American Journal of Physiology - Renal Physiology, 2017, 313, F184-F191.	1.3	46
61	Calcium channel blockade blunts the renal effects of acute nitric oxide synthase inhibition in healthy humans. American Journal of Physiology - Renal Physiology, 2017, 312, F870-F878.	1.3	3
62	Assessment of urinary microparticles in normotensive patients with type 1 diabetes. Diabetologia, 2017, 60, 581-584.	2.9	65
63	Sodium Glucose Cotransporter-2 Inhibition in Heart Failure. Circulation, 2017, 136, 1643-1658.	1.6	340
64	The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome. PLoS ONE, 2017, 12, e0186910.	1.1	21
65	Lower corneal nerve fibre length identifies diabetic neuropathy in older adults with diabetes: results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetologia, 2017, 60, 2529-2531.	2.9	14
66	Plasma uric acid effects on glomerular haemodynamic profile of patients with uncomplicated Type 1 diabetes mellitus. Diabetic Medicine, 2016, 33, 1102-1111.	1.2	19
67	The Gomez equations and renal hemodynamic function in kidney disease research. American Journal of Physiology - Renal Physiology, 2016, 311, F967-F975.	1.3	35
68	Sodiumâ€“glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney International, 2016, 89, 524-526.	2.6	105
69	Association Between Plasma Uric Acid Levels and Cardiorenal Function in Adolescents With Type 1 Diabetes. Diabetes Care, 2016, 39, 611-616.	4.3	22
70	New and old agents in the management of diabetic nephropathy. Current Opinion in Nephrology and Hypertension, 2016, 25, 232-239.	1.0	31
71	The effect of sex on humanin levels in healthy adults and patients with uncomplicated type 1 diabetes mellitus. Canadian Journal of Physiology and Pharmacology, 2015, 93, 239-243.	0.7	8
72	Uric Acid as a Biomarker and a Therapeutic Target in Diabetes. Canadian Journal of Diabetes, 2015, 39, 239-246.	0.4	103

#	Article	IF	Citations
73	Glomerular haemodynamic profile of patients with Type 1 diabetes compared with healthy control subjects. Diabetic Medicine, 2015, 32, 972-979.	1.2	15
74	Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. American Journal of Physiology - Renal Physiology, 2015, 308, F77-F83.	1.3	143
75	Repeated daily dosing with sildenafil provides sustained protection from endothelial dysfunction caused by ischemia and reperfusion: a human in vivo study. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H888-H894.	1.5	18
76	Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia, 2014, 57, 2599-2602.	2.9	136
77	Renal Hyperfiltration Is Associated With Glucose-Dependent Changes in Fractional Excretion of Sodium in Patients With Uncomplicated Type 1 Diabetes. Diabetes Care, 2014, 37, 2774-2781.	4.3	6